Hawn Jaclyn M, Bauer Seth R, Yerke Jason, Li Manshi, Wang Xiaofeng, Reddy Anita J, Mireles-Cabodevila Eduardo, Sacha Gretchen L
Department of Pharmacy, Medical University of South Carolina, Charleston, SC.
Department of Pharmacy, Cleveland Clinic, Cleveland, OH.
Chest. 2021 May;159(5):1875-1883. doi: 10.1016/j.chest.2020.11.051. Epub 2020 Dec 13.
IV pushes of phenylephrine may be used for patients with septic shock with the intent of rapidly achieving mean arterial pressure (MAP) goals. However, the clinical effectiveness and safety of this approach are unclear.
In patients with septic shock, is administration of a phenylephrine push before norepinephrine initiation associated with a higher incidence of hemodynamic stability?
This retrospective, multicenter cohort study included adult patients with septic shock initiated on norepinephrine. Propensity scores for initial phenylephrine push receipt were generated, and patients receiving an initial phenylephrine push were propensity score-matched 1:2 to those not receiving an initial phenylephrine push. The primary outcome was achievement of hemodynamic stability (defined as maintaining MAP of ≥ 65 mm Hg for at least 6 h without an increase in continuous infusion vasoactive agent dosage) within 3 and 12 h of norepinephrine initiation.
Of 1,317 included patients, 181 received an initial phenylephrine push; 141 phenylephrine push patients were matched to 282 patients not receiving a phenylephrine push. More patients who received a phenylephrine push achieved hemodynamic stability at hour 3 than those who did not receive a phenylephrine push (28.4% vs 18.8%; risk difference, 10%; 95% CI, 0.9%-18%). Phenylephrine push receipt was associated independently with hemodynamic stability within 3 h (adjusted OR, 1.8; 95% CI, 1.09-2.97), but not at 12 h (adjusted OR, 1.42; 95% CI, 0.93-2.16). Phenylephrine push receipt was associated independently with higher ICU mortality (adjusted OR, 1.88; 95% CI, 1.1-3.21).
Phenylephrine pushes were associated with a higher incidence of early, but not sustained, hemodynamic stability and were associated independently with higher ICU mortality. Caution is warranted when clinicians are considering the use of phenylephrine pushes in patients with septic shock.
去氧肾上腺素静脉推注可用于感染性休克患者,目的是快速达到平均动脉压(MAP)目标。然而,这种方法的临床有效性和安全性尚不清楚。
在感染性休克患者中,在开始使用去甲肾上腺素之前推注去氧肾上腺素是否与更高的血流动力学稳定性发生率相关?
这项回顾性多中心队列研究纳入了开始使用去甲肾上腺素的成年感染性休克患者。生成了初始接受去氧肾上腺素推注的倾向评分,接受初始去氧肾上腺素推注的患者与未接受初始去氧肾上腺素推注的患者按1:2进行倾向评分匹配。主要结局是在开始使用去甲肾上腺素后3小时和12小时内实现血流动力学稳定(定义为维持MAP≥65mmHg至少6小时且不增加持续输注血管活性药物剂量)。
在1317例纳入患者中,181例接受了初始去氧肾上腺素推注;141例接受去氧肾上腺素推注的患者与282例未接受去氧肾上腺素推注的患者进行了匹配。在3小时时,接受去氧肾上腺素推注的患者比未接受去氧肾上腺素推注的患者更多地实现了血流动力学稳定(28.4%对18.8%;风险差异,10%;95%CI,0.9%-18%)。接受去氧肾上腺素推注独立与3小时内的血流动力学稳定相关(校正OR,1.8;95%CI,1.09-2.97),但在12小时时不相关(校正OR,1.42;95%CI,0.93-2.16)。接受去氧肾上腺素推注独立与更高的ICU死亡率相关(校正OR,1.88;95%CI,1.1-3.21)。
去氧肾上腺素推注与早期但非持续性血流动力学稳定的较高发生率相关,且独立与较高的ICU死亡率相关。临床医生在考虑对感染性休克患者使用去氧肾上腺素推注时应谨慎。